Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 7;18(1):6.
doi: 10.1186/s13104-024-07032-y.

The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4+ T cell count irrespective of co-infection with tuberculosis

Affiliations

The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4+ T cell count irrespective of co-infection with tuberculosis

Funsho J Ogunshola et al. BMC Res Notes. .

Abstract

Background: Immune reconstitution following the initiation of combination antiretroviral therapy (cART) significantly impacts the prognosis of individuals infected with human immunodeficiency virus (HIV). Our previous studies have indicated that the baseline CD4+ T cells count and percentage before cART initiation are predictors of immune recovery in TB-negative children infected with HIV, with TB co-infection potentially causing a delay in immune recovery. However, it remains unclear whether these predictors consistently impact immune reconstitution during long-term intensive cART treatment in TB-negative/positive children infected with HIV.

Results: We confirmed that the baseline CD4+ T cell count is a significant predictor of immune recovery following long-term intensive cART treatment among children aged 0 to 13 years. Children with lower CD4+ T cell count prior cART initiation did not show substantial immunological recovery during the follow-up period. Interestingly, children who were co-infected with TB and had higher baseline CD4+ T cell count eventually achieved good immunological recovery comparable to the TB-negative HIV-infected children. Hence, the baseline CD4+ T cell count at the onset of treatment serves as a reliable predictor of immunological reconstitution in HIV-infected children with or without TB co-infection. Taken together, this follow-up study validates our previous findings and further establishes that initiating cART early alongside early HIV testing can help prevent the diminished CD4+ T cell count associated with inadequate immunological reconstitution.

Keywords: CART initiation; CD4+ T cell count; HIV; Immune recovery; Piecewise linear and mixed-effects models; TB.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the ethical standards of the institutional and/or national research committee and the Declaration of Helsinki. Informed consent to participate was obtained from the participants and the study protocol received approval from the Yale University Human Investigation Committee and the University of Ghana Medical School. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
CD4+ T-cell count trajectories among children treated at Korle-Bu Teaching Hospital
Fig. 2
Fig. 2
CD4+ T-cell count trajectories by recovery status among children treated at Korle-Bu Teaching Hospital
Fig. 3
Fig. 3
CD4+ T-cell counts trajectories by recovery status among TB negative (left) and TB positive (right) children treated at Korle-Bu Teaching Hospital

Update of

Similar articles

References

    1. Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV coinfection. Cold Spring Harb Perspect Med. 2015;5: a017871. 10.1101/cshperspect.a017871. - PMC - PubMed
    1. Torpey K, et al. Management of TB/HIV co-infection: the state of the evidence. Ghana Med J. 2020;54:186–96. 10.4314/gmj.v54i3.10. - PMC - PubMed
    1. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005;293:2767–75. 10.1001/jama.293.22.2767. - PubMed
    1. Lawn SD, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10:489–98. 10.1016/s1473-3099(10)70078-5. - PubMed
    1. Günthard HF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316:191–210. 10.1001/jama.2016.8900. - PMC - PubMed

MeSH terms

Substances